When did Gilead Sciences Inc file this 8-K?

Gilead Sciences Inc (GILD) filed this Current Report (Form 8-K) with the SEC on May 4, 2026. The accession number assigned by EDGAR is 0000882095-26-000008.

What does an 8-K disclose?

Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).

What is the key takeaway from this filing?

Gilead stockholders elected nine directors, approved key governance actions (equity plan, pay, auditor) and rejected independence/ESG proposals. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.

What Item codes does an 8-K cover?

An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.

Where can I find Gilead Sciences Inc's prior current reports on EDGAR?

The SEC EDGAR browser lists every 8-K Gilead Sciences Inc has filed under CIK 882095, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.

Boardroom Alpha

GILD · Current Report (Form 8-K) · Filed May 4, 2026

Gilead Sciences Inc — Current Report (Form 8-K)

Form

8-K

Filed

May 4, 2026

Period

Apr 30, 2026

Ticker

GILD

Accession

0000882095-26-000008

Gilead Sciences Inc on Boardroom Alpha View on SEC EDGAR

Boardroom Alpha · Filing insights

Gilead stockholders elected nine directors, approved key governance actions (equity plan, pay, auditor) and rejected independence/ESG proposals.

About Gilead Sciences Inc

Market cap

$158.4B

1Y TSR

+23.8%

3Y TSR

+23.5%

Board grade

B-

Sector

Healthcare

CEO

Daniel P O'Day

Last annual meeting: Apr 30, 2026 · View full Gilead Sciences Inc profile →

gild-20260430

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 30, 2026

GILEAD SCIENCES, INC.

(Exact name of registrant as specified in its charter)


Delaware	000-19731	94-3047598
(State or Other Jurisdiction of Incorporation)	(Commission File No.)	(IRS Employer Identification No.)

333 Lakeside Drive, Foster City, California

(Address of principal executive offices)

94404

(Zip Code)

650-574-3000

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value, $0.001 per share

GILD

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.07 Submission of Matters to a Vote of Security Holders.

The 2026 annual meeting of stockholders (the “Annual Meeting”) of Gilead Sciences, Inc. (the “Company”) was held on April 30, 2026. Of the 1,241,222,013 shares of the Company’s common stock entitled to vote at the Annual Meeting, 1,130,179,690 shares were represented at the beginning of the meeting in person or by proxy, which constituted a quorum. The voting results are presented below.

The Company’s stockholders elected nine directors to serve for the next year and until their successors are elected and qualified. The votes regarding the election of directors were as follows:


Name	Votes For	Votes Against	Abstentions	Broker Non-Votes
Jacqueline K. Barton, Ph.D.	1,013,176,696	21,056,724	938,657	95,008,389
Jeffrey A. Bluestone, Ph.D.	1,017,337,149	16,873,041	961,887	95,008,389
Sandra J. Horning, M.D.	1,002,426,858	31,078,619	1,666,600	95,008,389
Kelly A. Kramer	995,947,854	38,240,224	983,999	95,008,389
Ted W. Love, M.D.	1,016,607,688	17,592,385	972,004	95,008,389
Harish Manwani	995,710,468	38,469,820	991,789	95,008,389
Daniel P. O’Day	980,597,212	50,179,985	4,394,880	95,008,389
Javier J. Rodriguez	1,019,197,783	15,002,200	972,094	95,008,389
Anthony Welters	992,619,897	40,842,646	1,709,534	95,008,389

The Company’s stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The proposal received the following votes:


Votes For						1,046,350,569
Votes Against						82,831,295
Abstentions						998,602

The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s Named Executive Officers as presented in the Proxy Statement. The proposal received the following votes:


Votes For						954,325,805
Votes Against						77,503,947
Abstentions						3,342,325
Broker Non-Votes						95,008,389

The Company’s stockholders approved the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan. The proposal received the following votes:


Vote For						970,290,586
Vote Against						62,501,433
Abstentions						2,380,058
Broker Non-Votes						95,008,389

The Company’s stockholders did not approve a stockholder proposal requesting an independent Board Chair policy. The proposal received the following votes:


Votes For						280,044,780
Votes Against						752,716,225
Abstentions						2,411,072
Broker Non-Votes						95,008,389

The Company’s stockholders did not approve a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access. The proposal received the following votes:


Votes For						134,042,210
Votes Against						886,986,584
Abstentions						14,143,283
Broker Non-Votes						95,008,389

The Company’s stockholders did not approve a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics. The proposal received the following votes:


Votes For						7,262,421
Votes Against						1,022,330,186
Abstentions						5,579,470
Broker Non-Votes						95,008,389

Item 9.01 - Financial Statements and Exhibits

(d): The following exhibits are being filed herewith:


Exhibit No.						Description
10.1						Gilead Sciences, Inc. 2022 Equity Incentive Plan, amended and restated April 30, 2026
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


GILEAD SCIENCES, INC.
(Registrant)
/s/ Keeley M. Cain Wettan
Keeley M. Cain Wettan
Executive Vice President, General Counsel, Legal and Compliance, and Secretary

Date: May 04, 2026

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

See Filings Intelligence Schedule a Demo

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Gilead Sciences Inc (GILD)

8-KCurrent Report
May 20, 2026
10-QQuarterly Report
May 7, 2026
8-KCurrent Report
May 7, 2026
8-KCurrent Report
Apr 28, 2026
DEFA14AAdditional Proxy Materials
Mar 20, 2026
DEF 14AProxy Statement
Mar 20, 2026
10-KAnnual Report
Feb 24, 2026
8-KCurrent Report
Feb 23, 2026
8-KCurrent Report
Feb 10, 2026
8-KCurrent Report
Nov 19, 2025
10-QQuarterly Report
Nov 7, 2025
8-KCurrent Report
Oct 30, 2025

Continue researching

Reference

Frequently asked questions

When did Gilead Sciences Inc file this 8-K?: Gilead Sciences Inc (GILD) filed this Current Report (Form 8-K) with the SEC on May 4, 2026. The accession number assigned by EDGAR is 0000882095-26-000008.
What does an 8-K disclose?: Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?: Gilead stockholders elected nine directors, approved key governance actions (equity plan, pay, auditor) and rejected independence/ESG proposals. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?: An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Gilead Sciences Inc's prior current reports on EDGAR?: The SEC EDGAR browser lists every 8-K Gilead Sciences Inc has filed under CIK 882095, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer